18:25 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Sienna planning Phase III trials of pegcantratinib in psoriasis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) plans to start Phase III trials in 2H19 of pegcantratinib (SNA-120) to treat psoriasis despite reporting that the compound missed the primary endpoint in a Phase IIb trial to treat pruritus...
17:16 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris. The candidate is a topical photoparticle therapy targeting the sebaceous...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
20:29 , Mar 23, 2018 |  BC Extra  |  Company News

Management tracks: Sienna, Origenis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said CFO Richard Peterson will retire, effective at the end of April. He will be succeeded by John Smither, who was CFO at Novan Inc. (NASDAQ:NOVN). Sienna also hired Caroline Van...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
21:27 , Jul 28, 2017 |  BC Week In Review  |  Financial News

Sienna raises $65M in IPO

On July 26, dermatology company Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) raised $65 million through the sale of 4.3 million shares at $15 in an IPO on NASDAQ underwritten by JPMorgan, Cowen and BMO Capital Markets. Sienna...
15:23 , Jul 27, 2017 |  BC Extra  |  Financial News

Sienna rises after pricing $65M IPO

Dermatology company Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) gained $4.25 (28%) to $19.25 on Thursday after raising $65 million through the sale of 4.3 million shares at $15 in an IPO on NASDAQ underwritten by JPMorgan, Cowen...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
20:40 , Jul 7, 2017 |  BC Week In Review  |  Financial News

Sienna proposes $74.8M IPO

On July 3, dermatology company Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.) proposed to raise up to $74.8 million in an IPO on NASDAQ underwritten by JPMorgan, Cowen and BMO Capital Markets. Sienna Biopharmaceuticals Inc. ,...